Capricor Therapeutics Inc (NASDAQ:CAPR) shares, rose in value on Wednesday, February 12, with the stock price up by 11.65% to the previous day’s close as strong demand from buyers drove the stock to $15.05.
Actively observing the price movement in the last trading, the stock closed the session at $13.48, falling within a range of $13.2201 and $15.46. Referring to stock’s 52-week performance, its high was $23.40, and the low was $3.52. On the whole, CAPR has fluctuated by 18.32% over the past month.
With the market capitalization of Capricor Therapeutics Inc currently standing at about $684.32 million, investors are eagerly awaiting this quarter’s results, scheduled for in March.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 9.87M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CAPR’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of 50% Buy while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the price of CAPR currently trading nearly 4.72% and 4.79% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 55.25, while the 7-day volatility ratio is showing 7.35% which for the 30-day chart, stands at 6.49%. Furthermore, Capricor Therapeutics Inc (CAPR)’s beta value is 4.12, and its average true range (ATR) is 0.99.
A comparison of Capricor Therapeutics Inc (CAPR) with its peers suggests the former has fared considerably weaker in the market. CAPR showed an intraday change of 11.65% in last session, and over the past year, it grew by 284.91%%.
Data on historical trading for Capricor Therapeutics Inc (NASDAQ:CAPR) indicates that the trading volumes over the past 10 days have averaged 0.75 and over the past 3 months, they’ve averaged 1.19 million. According to company’s latest data on outstanding shares, there are 40.33 million shares outstanding.
Nearly 12.08% of Capricor Therapeutics Inc’s shares belong to company insiders and institutional investors own 24.62% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 7.67 million shares as on 2025-01-31, resulting in a short ratio of 9.61. According to the data, the short interest in Capricor Therapeutics Inc (CAPR) stood at 1913.00 of shares outstanding as of 2025-01-31; the number of short shares registered in 2024-12-31 reached 7.95 million. The stock has risen by 9.06% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CAPR stock heading into the next quarter.
